GlassScriptPhysician profile
M Pierre P Pang
NPI 1487654794
$9,672.70
in general payments reported to CMS, 2019-2025
28 companies · $2,089 in 2025
The $2,089 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,723 · 2020: $776 · 2021: $934 · 2022: $895 · 2023: $789 · 2024: $1,466 · 2025: $2,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,344.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,073.13 | 2019-2020 | |
| Alcon Vision LLC | $1,262.33 | 2019-2025 | Rocklatan, Unity, Clareon Panoptix Pro |
| Abbvie INC. | $986.21 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $921.10 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $905.82 | 2019-2025 | Cequa, Xelpros |
| Bausch & Lomb Americas INC. | $440.31 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $404.19 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $361.58 | 2019-2021 | |
| Amgen INC. | $328.68 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $303.21 | 2021-2022 | |
| Allergan, INC. | $292.62 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $253.97 | 2020-2025 | Eylea Hd, Eylea |
| Oyster Point Pharma, INC. | $196.55 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $160.73 | 2024 | Ilevro |
| Tarsus Pharmaceuticals, INC. | $113.67 | 2024-2025 | Xdemvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $104.54 | 2022-2025 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $103.93 | 2024 | Eylea, Eylea Hd |
| Dompe US, INC. | $87.18 | 2025 | Oxervate |
| Glaukos Corporation | $71.12 | 2025 | Idosetr, Istent, Photrexa Viscous and Photrexa |
| Horizon Therapeutics Plc | $62.29 | 2022-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $51.19 | 2020 | |
| Eyepoint US, INC. | $43.91 | 2023 | |
| Sight Sciences, INC. | $29.69 | 2019-2021 | |
| Biogen, INC. | $27.32 | 2023 | |
| Mallinckrodt Enterprises LLC | $24.64 | 2019 | |
| Astellas Pharma US INC | $24.42 | 2023 | |
| Shire North American Group INC | $22.75 | 2019 | |
| Eyevance Pharmaceuticals LLC | $15.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Pierre Pang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.